Dergiler / art / 2020 / Cilt: 35 - Sayı: 4

A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy

Dergi
art
Sayfa
618–622
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In this article, we present a 48-year-old female patient diagnosed with PM nearly 13 years ago that did not sufficiently respond to the pharmaceutical agents that were indicated for the conventional treatment of the disease and developed femoral head avascular necrosis because of the treatment and was, in the end, successfully treated with abatacept monotherapy at our clinic.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Polymyositis (PM) is an autoimmune disease progressing in the form of a break down of the muscles that is induced by chronic inflammation in skeletal muscles.
📊
Temel Bulgular & Veri:Muscle weakness is painless and concentrates on proximal muscles, involving the pectoral and pelvic girdle.
💡
Sonuç & Katkı:In this article, we present a 48-year-old female patient diagnosed with PM nearly 13 years ago that did not sufficiently respond to the pharmaceutical agents that were indicated for the conventional treatment of the disease and developed femoral head avascular necrosis because of the treatment and was, in the end, successfully treated with abatacept monotherapy at our clinic.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Polymyositis (PM) is an autoimmune disease progressing in the form of a break down of the muscles that is induced by chronic inflammation in skeletal muscles. Muscle weakness is painless and concentrates on proximal muscles, involving the pectoral and pelvic girdle. If the disease is not treated properly, it may progress and lead to a considerable decrease in the quality of life. Its conventional treatment involves drugs that suppress inflammation such as steroids, methotrexate, azathioprine, and intravenous immunoglobulin. However, conventional treatment may prove insufficient to halt the progression of the disease and offer only a limited improvement because of the adverse effects it causes in some patients. In this article, we present a 48-year-old female patient diagnosed with PM nearly 13 years ago that did not sufficiently respond to the pharmaceutical agents that were indicated for the conventional treatment of the disease and developed femoral head avascular necrosis because of the treatment and was, in the end, successfully treated with abatacept monotherapy at our clinic.

🔖

Bu Makaleye Atıf Yap

ÇAĞLAYAN, M., IŞIK, H., OKTAYOĞLU, P. (2020). A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy. art, Cilt: 35 - Sayı: 4, 618–622. https://ajindex.com/articles/351648

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013;88:83-105
  2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82
  3. Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis-a case-based review. Clin Rheumatol 2015;34:609-12
  4. Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasová Studynková J, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis 2018;77:55-62
  5. Musuruana JL, Cavallasca JA. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 2011;78:431-2
  6. Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 2014;53:379-80
  7. Grundtman C, Lundberg IE. Pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2006;8:188-95
  8. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010;1184:134-53
  9. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 2012;24:635-41
  10. Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 2014;175:349-58
  11. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24
  12. Iannone F, Lapadula G. The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl 2012;Suppl 89:100-2
  13. Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol 2014;26:704-11
  14. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 2009;80:1060-8
  15. Catoggio LJ, Managemant of inflammatory muscle disease. In: Hochberg MC, Silman AJ, Slomen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Mosby (Elsevier); 2007. p. 1461-8
  16. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum 1981;24:45-8
  17. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin in